| Identification | Back Directory | [Name]
Lasofoxifene | [CAS]
180916-16-9 | [Synonyms]
(5R,6S)-
CP-336,156
Lasofoxifene
Lasofoxifene Base
(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]tetralin-2-ol
(5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol
(5R-cis)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol
2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- | [Molecular Formula]
C28H31NO2 | [MDL Number]
MFCD09475650 | [MOL File]
180916-16-9.mol | [Molecular Weight]
413.55 |
| Chemical Properties | Back Directory | [Melting point ]
110-113°C | [Boiling point ]
572.4±50.0 °C(Predicted) | [density ]
1.150±0.06 g/cm3(Predicted) | [storage temp. ]
Refrigerator | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
10.31±0.60(Predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White Solid | [Uses]
A next-generation selective estrogen receptor modulator for treating disorders associated with increased bone turnover and osteopenia. | [Definition]
ChEBI: Lasofoxifene is a member of the class of tetralins that is 5,6,7,8-tetrahydronaphthalen-2-ol in which the hydrogens at positions 5 and 6 are replaced by 4-[2-(pyrrolidin-1-yl)ethoxy]phenyl and phenyl groups, respectively (the 5R,6S-stereoisomer). It is a selective estrogen receptor modulator indicated for the prevention and treatment of osteoporosis in post-menopausal women. It has a role as an antineoplastic agent, a cardioprotective agent, an estrogen receptor agonist, an estrogen receptor antagonist and a bone density conservation agent. It is a member of tetralins, an aromatic ether, a member of naphthols and a N-alkylpyrrolidine. | [Clinical Use]
Lasofoxifene is a very potent second-generation SERM currently in phase III clinical trials for the treatment and
prevention of osteoporosis in postmenopausal women. | [in vivo]
Lasofoxifene (4 mg/mice; s.c.; 5 day/week; for 43 d) decreases arthritis severity, by reducing cartilage oligomeric matrix protein (COMP), the serum marker of cartilage destruction and reducing serum IL-6 (inflammatory cytokine) levels in mice[1].
Lasofoxifene (4 mg/mice; s.c.; 5 day/week; for 43 d) protects against generalised bone loss in CIA by increasing trabecular bone mineral density (BMD), cortical thickness in mice[1].
Lasofoxifene (5, and 10 mg/kg; s.c.; 5 day/week; for 70 d) exerts function of inhibiting primary tumor growth and reducing metastases to the lung and the liver in mice[3].
| Animal Model: | Post-menopausal RA model on OVX (ovariectomised) DBA/1 mice (female DBA/1 mice, 8-10 weeks old, CIA-treated)[1] | | Dosage: | 4 mg/mouse/day | | Administration: | Subcutaneous injection; 5 days a week from the first signs of arthritis (day 18); 43 days | | Result: | Reduced in arthritis severity, including synovial inflammation and destruction of joints reduction.
The mean arthritis frequency was 47% while the vehicle group was 81% at 42 days post immunization. |
| Animal Model: | NSG mices with xenograft tumors model (MIND, mammary intraductal): WT, Y537S and D538G ERα render tumors[3] | | Dosage: | 1, 5, or 10 mg/kg | | Administration: | Subcutaneous injection; 5 days per week; for 70 days | | Result: | Elicited a superior inhibitory effect at a dose of 10 mg/kg, resulted potential tumor shrinkage in Y537S and D538G tumors.
And also reduced tumor weight to 60% for Y537S and 50% for D538G at 5 and 10 mg/kg, respectively. |
|
|
|